Submit Content
Get the latest delivered to your inbox
Privacy Policy

Alkermes

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

    New Survey Provides Insights Into Drinking Behaviors During the Pandemic Image

    POSTED 

    09-22-21

    New Survey Provides Insights Into Drinking Behaviors During the Pandemic

    A new online survey conducted during the COVID-19 pandemic by The Harris Poll on behalf of Alkermes found that 17% of respondents aged 21 and over reported drinking patterns that met the survey criteria for "heavy drinking"*.
    Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program Image

    POSTED 

    09-13-21

    Alkermes Announces Launch of 4th Annual Alkermes Pathways Research Awards® Program

    Alkermes will begin accepting applications for its annual Alkermes Pathways Research Awards® program on 9/13/2021. This competitive grant program supports researchers working to advance understanding & awareness of disease states in neuroscience.
    Alkermes Sr. Director of Oncology Discusses Career, Inspirational Women in STEM Image

    POSTED 

    08-24-21

    Alkermes Sr. Director of Oncology Discusses Career, Inspirational Women in STEM

    Heather Losey Ph.D., Senior Director, Research Oncology Program Lead at Alkermes, sits down with Authority Magazine to discuss her career in a series highlighting inspirational women in STEM.
    Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program Image

    POSTED 

    07-23-21

    Alkermes Announces Recipients of 2021 Alkermes Inspiration Grants® Program

    Grants were awarded to 11 nonprofits working to address the needs of people living with addiction, serious mental illness or cancer, including programs serving historically under-resourced or underrepresented communities.
    Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign Image

    POSTED 

    06-24-21

    Alkermes Announces Former Professional Baseball Player, CC Sabathia, as Spokesperson for Alcohol Dependence Awareness Campaign

    Alkermes, Inc., a subsidiary of Alkermes plc (Nasdaq: ALKS), recently announced former professional baseball player and World Series champion, CC Sabathia, as a spokesperson for the company's My Relationship with Alcohol campaign, which is designed to help raise awareness about the disease of alcoho...
    The Boston Club Recognizes Alkermes plc and Blue Cross Blue Shield of Massachusetts With First President's Award Image

    POSTED 

    05-17-21

    The Boston Club Recognizes Alkermes plc and Blue Cross Blue Shield of Massachusetts With First President's Award

    Alkermes plc is a recipient of The Boston Club’s first President’s Award, recognizing organizations that are leaders in supporting the advancement of women in the C-suite and boardroom.
    Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer Image

    POSTED 

    05-13-21

    Alkermes Announces 2021 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer

    Alkermes plc (Nasdaq: ALKS) today announced that the company will begin accepting applications for its Alkermes Inspiration Grants® program beginning on May 20, 2021.
    Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month Image

    POSTED 

    05-04-21

    Alkermes to Showcase Data From Psychiatry Portfolio at Upcoming Scientific Conferences Throughout Mental Health Awareness Month

     Alkermes plc (Nasdaq: ALKS) recently announced plans to present clinical data and outcomes research from its psychiatry portfolio at three scientific conferences during Mental Health Awareness Month in May. The meetings, all held virtually, include:
    Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic Image

    POSTED 

    11-04-20

    Harris Poll Survey Offers Insights into Potential of Telepsychiatry During and After the COVID-19 Pandemic

    As the use of telehealth services has expanded during the COVID-19 pandemic, results from a survey conducted by The Harris Poll showed that more than one in four (27%) U.S. adults surveyed were currently using telepsychiatry (“telepsych”) services for mental health care.
    Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience Image

    POSTED 

    09-15-20

    Alkermes Presents New Psychiatry Data at Psych Congress 2020 Virtual Experience

    Alkermes plc (Nasdaq: ALKS) recently announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at the Psych Congress 2020 Virtual Experience, held Sept. 10-13, 2020.
    Alkermes logo

    Alkermes

    Alkermes

    Join today and get the latest delivered to your inbox